Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ki20227 是一种高效的、口服具有活性的、选择性的CSF1R(c-Fms 酪氨酸激酶)抑制剂,对 CSF1R,VEGFR2,c-Kit 和PDGFRβ的IC50分别为 2 nM,12 nM,451 nM 和 217 nM。它可以阻止破骨细胞分化和溶骨性破坏。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 437 | 现货 | ||
2 mg | ¥ 632 | 现货 | ||
5 mg | ¥ 1,110 | 现货 | ||
10 mg | ¥ 1,620 | 现货 | ||
25 mg | ¥ 3,210 | 现货 | ||
50 mg | ¥ 4,680 | 现货 | ||
100 mg | ¥ 6,680 | 现货 | ||
500 mg | ¥ 13,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,170 | 现货 |
产品描述 | Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451/217 nM), respectively. |
靶点活性 | VEGFR2:12 nM, CSF1R:2 nM |
体外活性 | Ki20227 hasn't inhibition for other kinases tested, such as EGFR, Fms-like tyrosine kinase-3, or c-Src (c-src proto-oncogene product). Ki20227 also inhibits the M-CSF-dependent growth of M-NFS-60 cells but not the M-CSF-independent growth of A375 human melanoma cells in vitro. Ki20227 has an inhibition against M-CSF-dependent reactions, such as lipopolysaccharide-induced TNF-α production, which was enhanced by M-CSF in vitro. |
体内活性 | Ki20227 reduces the number of tartrate-resistant acid phosphatase-positive osteoclast-like cells on bone surfaces in ovariectomized (ovx) rats. Furthermore, in the Ki20227-treated mice, the number of CD11b(+), Gr-1(+), and Ly-6 g(+) cells in the spleen were decreased and the CII-induced cytokine production in splenocytes isolated from the Ki20227-treated arthritic mice was also reduced. In EAE animal model, Ki20227 inhibits the turn-over/expansion of myeloid cells provoked by the immunization and subsequent MOG-specific T cell responses. |
别名 | N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 |
分子量 | 480.54 |
分子式 | C24H24N4O5S |
CAS No. | 623142-96-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (114.45 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.081 mL | 10.405 mL | 20.8099 mL | 52.0248 mL |
5 mM | 0.4162 mL | 2.081 mL | 4.162 mL | 10.405 mL | |
10 mM | 0.2081 mL | 1.0405 mL | 2.081 mL | 5.2025 mL | |
20 mM | 0.104 mL | 0.5202 mL | 1.0405 mL | 2.6012 mL | |
50 mM | 0.0416 mL | 0.2081 mL | 0.4162 mL | 1.0405 mL | |
100 mM | 0.0208 mL | 0.104 mL | 0.2081 mL | 0.5202 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ki20227 623142-96-1 Angiogenesis Tyrosine Kinase/Adaptors VEGFR c-Fms c-Kit PDGFR CSF-1R N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 inhibit Vascular endothelial growth factor receptor CD117 CSF1R SCFR Ki 20227 colony stimulating factor 1 receptor CSF-1 receptor Platelet-derived growth factor receptor Ki-20227 Inhibitor inhibitor